Interleukin-25 induces type 2 cytokine production in a steroid-resistant interleukin-17RB+ myeloid population that exacerbates asthmatic pathology
Open Access
- 29 April 2012
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 18 (5) , 751-758
Abstract
Interleukin-25 (IL-25) is released from lung epithelial cells in response to allergen challenge and promotes type 2 immune responses and allergic airway inflammation. Nicholas Lukacs and his colleagues now report that IL-25 acts on a myeloid population in the lung. These cells represent a major source of IL-4 and IL-13, promote allergic lung inflammation and are steroid resistant. The frequency of IL-4– and IL-13–producing myeloid cells is increased in individuals with asthma, suggesting these cells may have a crucial role in the development of asthma. Interleukin-25 (IL-25) is a cytokine associated with allergy and asthma that functions to promote type 2 immune responses at mucosal epithelial surfaces and serves to protect against helminth parasitic infections in the intestinal tract. This study identifies the IL-25 receptor, IL-17RB, as a key mediator of both innate and adaptive pulmonary type 2 immune responses. Allergen exposure upregulated IL-25 and induced type 2 cytokine production in a previously undescribed granulocytic population, termed type 2 myeloid (T2M) cells. Il17rb−/− mice showed reduced lung pathology after chronic allergen exposure and decreased type 2 cytokine production in T2M cells and CD4+ T lymphocytes. Airway instillation of IL-25 induced IL-4 and IL-13 production in T2M cells, demonstrating their importance in eliciting T cell–independent inflammation. The adoptive transfer of T2M cells reconstituted IL-25–mediated responses in Il17rb−/− mice. High-dose dexamethasone treatment did not reduce the IL-25–induced T2M pulmonary response. Finally, a similar IL-4– and IL-13–producing granulocytic population was identified in peripheral blood of human subjects with asthma. These data establish IL-25 and its receptor IL-17RB as targets for innate and adaptive immune responses in chronic allergic airway disease and identify T2M cells as a new steroid-resistant cell population.Keywords
This publication has 58 references indexed in Scilit:
- IL25 elicits a multipotent progenitor cell population that promotes TH2 cytokine responsesNature, 2010
- Nuocytes represent a new innate effector leukocyte that mediates type-2 immunityNature, 2010
- MHC class II–dependent basophil–CD4+ T cell interactions promote TH2 cytokine–dependent immunityNature Immunology, 2009
- Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 2009
- Chapter 5 Immune Pathways for Translating Viral Infection into Chronic Airway Disease2009
- Persistent activation of an innate immune response translates respiratory viral infection into chronic lung diseaseNature Medicine, 2008
- IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC–activated Th2 memory cellsJournal of Experimental Medicine, 2007
- Interleukin 25 promotes the initiation of proallergic type 2 responsesJournal of Experimental Medicine, 2007
- Type 2 immunity is controlled by IL-4/IL-13 expression in hematopoietic non-eosinophil cells of the innate immune systemJournal of Experimental Medicine, 2006
- Identification of an interleukin (IL)-25–dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsionJournal of Experimental Medicine, 2006